Enveric Biosciences, Inc. (NASDAQ: ENVB), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for...
The company said it progressed toward obtaining federal patents on synthetic psychedelic drugs. The post Enveric Biosciences Loses $6.4 Million in Q2,...
Atai Life Sciences (NASDAQ: ATAI) reported its second quarter 2023 financial results and provided corporate updates. At this time Atai has no revenue to...
Atai noted it was exploring strategic options for the study. The post Atai May Step Away from Ketamine Study After Releasing Positive Results appeared...
Atai announced results from Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine). The post atai Life...
Local markets are flat at lunchtime, despite a push among banking stocks and some huge lithium news for Iris Metals. ... Read More The post ASX...
FDA has approved two clinical trials studying the effects of PEX010, Filament's botanical psilocybin drug candidate. The post Filament Health Announces...
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed The post News...
FREMONT, CA, Aug. 07, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC)... The post ABVC Corporate Update and CEO’s...
MindMed released its Q3 financial results. Highlights include enrolment in Phase 2b LSD trial, top-line results by end-of-year, and $116 million in cash. The...